(A) LPS levels were analyzed in the active phase and one-month post-treatment (1 mpt) in VL patients and in healthy volunteers. (B) The insert shows the LPS levels from the same patients prospectively evaluated in two different time points (n = 22). Each symbol represents one patient. The horizontal bar represents the median values. Asterisks denote a statistically significant difference between groups, *p<0.05; **p<0.01.</p
Recently, there has been a renewed interest in the development of new drugs for the treatment of lei...
BACKGROUND: Leishmaniasis remains a serious public health problem in several parts of the developing...
Background: Visceral leishmaniasis (VL) is characterized by parasite-specific immunosuppression besi...
(A) Leptin levels of VL patients in the active phase (n = 31), after one-month post-treatment (1 mpt...
(A) IL-6 and (C) IL-10 levels were analyzed in the active phase and one-month post-treatment (1 mpt)...
(A and C) IgG1 and IgG3 levels of VL patients in the active phase, after one-month post-treatment (1...
<p>(A) Western blot of mature IL-1β (17 kDa) in 4 controls (1–4), 9 LCL patients (5–13) and 7 DCL pa...
is associated with the development and severity of disease.Sera from patients with confirmed diagno...
is associated with the development and severity of disease.Sera from patients with confirmed diagno...
Introduction Visceral leishmaniasis (VL) is caused by the intracellular protozoan Leishmania donovan...
Visceral leishmaniasis (VL) has a fatal course if not properly treated. Recovery from VL is linked t...
Introduction Visceral leishmaniasis (VL) is caused by the intracellular protozoan Leishmania donovan...
BACKGROUND: Leishmaniasis remains a serious public health problem in several parts of the developing...
Abstract Background Visceral leshimaniasis is a parasitic disease characterized by systemic infectio...
Introduction Visceral leishmaniasis (VL) is caused by the intracellular protozoan Leishmania donovan...
Recently, there has been a renewed interest in the development of new drugs for the treatment of lei...
BACKGROUND: Leishmaniasis remains a serious public health problem in several parts of the developing...
Background: Visceral leishmaniasis (VL) is characterized by parasite-specific immunosuppression besi...
(A) Leptin levels of VL patients in the active phase (n = 31), after one-month post-treatment (1 mpt...
(A) IL-6 and (C) IL-10 levels were analyzed in the active phase and one-month post-treatment (1 mpt)...
(A and C) IgG1 and IgG3 levels of VL patients in the active phase, after one-month post-treatment (1...
<p>(A) Western blot of mature IL-1β (17 kDa) in 4 controls (1–4), 9 LCL patients (5–13) and 7 DCL pa...
is associated with the development and severity of disease.Sera from patients with confirmed diagno...
is associated with the development and severity of disease.Sera from patients with confirmed diagno...
Introduction Visceral leishmaniasis (VL) is caused by the intracellular protozoan Leishmania donovan...
Visceral leishmaniasis (VL) has a fatal course if not properly treated. Recovery from VL is linked t...
Introduction Visceral leishmaniasis (VL) is caused by the intracellular protozoan Leishmania donovan...
BACKGROUND: Leishmaniasis remains a serious public health problem in several parts of the developing...
Abstract Background Visceral leshimaniasis is a parasitic disease characterized by systemic infectio...
Introduction Visceral leishmaniasis (VL) is caused by the intracellular protozoan Leishmania donovan...
Recently, there has been a renewed interest in the development of new drugs for the treatment of lei...
BACKGROUND: Leishmaniasis remains a serious public health problem in several parts of the developing...
Background: Visceral leishmaniasis (VL) is characterized by parasite-specific immunosuppression besi...